Navigation Links
Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer
Date:6/5/2010

CHICAGO, June 5 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties. The findings were announced today at the 2010 American Society of Clinical Oncology Annual Meeting.

(Logo: http://photos.prnewswire.com/prnh/20071106/KARMANOSLOGO )

Preclinical data suggests that bisphosphonates exhibit anti-tumor activity. Karmanos researchers, led by Zeina Nahleh, M.D., F.A.C.P., co-leader of the Breast Cancer Multidisciplinary Team and assistant professor of Internal Medicine at Karmanos and Wayne State University School of Medicine, conducted a two-year retrospective study that extracted data from the Metropolitan Detroit Cancer Surveillance System, a Surveillance, Epidemiology, and End Results registry.

A total of 696 patients 50 years and older with Stage I, II and III invasive breast cancer, diagnosed between 2000 and 2003, were included in the study. Ninety-seven women, or 14 percent of study participants, used nitrogen-containing bisphosphonates. The difference in overall survival between bisphosphonate users and non-users was not statistically significant at three years, with overall survival equating to 94 percent of bisphosphonate users and 88 percent of non-users.

However, after adjusting for differences between the groups in age, disease stage, hormone receptor status, endocrine therapy and vitamin D and calcium use, there was a marginally significant difference of 0.07 (on a scale of 0.00 to 1.00) in the three-year survival probability rate between users and non-users, favoring bisphosphonate non-users. In other words, what was thought to have anti-tumor properties appeared to be causing a poorer survival rate in bisphosphonate users as compared to non-users.

Dr. Nahleh said that results are preliminary and that more work needs to occur to understand why bisphosphonates may be lowering the survival rates in some female patients.

"This is just an eye-opener for us to await more studies on bisphosphonates and women with nonmetastatic breast cancer," she said. "It's something worth looking at and we still have a lot of work to do on this subject."

Dr. Nahleh mentioned that bisphosphonates are a regularly prescribed treatment for women with metastatic breast cancer, meant to ward off cancer cells from invading the bones. Because of their reported anti-tumor activity, some doctors may be inclined to prescribe them for women with nonmetastatic breast cancer for their possible anti-cancer properties. But this practice should be currently discouraged until the availability of the results from large ongoing prospective trials, according to Dr. Nahleh.

"The reason for our study is we are looking for improved outcomes in women with early stage breast cancer," she said. "We are evaluating the results from this study. But right now, I think we're justified in saying to these nonmetastatic breast cancer patients, let's wait until we get more data before we prescribe bisphosphonates."

There are randomized trials occurring right now to study bisphosphonate use in an adjuvant setting. Dr. Nahleh said the next step is to conduct more clinical and pre-clinical trials on bisphosphonates on nonmetastatic breast cancer patients and understanding the effects of these drugs on the different types of breast cancer.

Dr. Nahleh said that extensive research was undertaken by Ashish Bhargava, M.D., a resident of Internal Medicine at Wayne State University School of Medicine and Kavita Nirmal, M.D., who at the time of the study was serving a fellowship in the Hematology/Oncology Department at Wayne State University School of Medicine. Judith Abrams, Ph.D., director of the Biostatistics Core at Karmanos and professor of Internal Medicine at Wayne State University Medical Center, and John Graff, Ph.D., MS, former epidemiologist at the Karmanos Cancer Institute, also assisted in the study.

"I hope this study will open venues for more confirmatory research to be conducted," she said. "That's the main question that needs to be answered – does nitrogen-containing bisphosphonates cause a lower survival rate in some women with nonmetastatic breast cancer and which group of patients can be affected?"

Located in mid-town Detroit, Michigan, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for nearly 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 physicians and researchers on faculty at the Wayne State University School of Medicine, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate all forms of cancer. Its long-term partnership with the WSU School of Medicine enhances the collaboration of critical research and academics related to cancer care. Karmanos is southeastern Michigan's most preferred hospital for cancer care according to annual surveys conducted by the National Research Corporation. Gerold Bepler, M.D., Ph.D., is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to www.karmanos.org.


'/>"/>
SOURCE Barbara Ann Karmanos Cancer Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Karmanos Cancer Institutes Delphinus Receives $8 Million in Venture Capital for Product Development of Breast Cancer Imaging Tool
2. Karmanos Cancer Center Surgeon is Michigans First to Perform Transoral Robotic Surgery on Patients
3. Karmanos Cancer Institute Launches Company and Innovative Breast Imaging Tool
4. International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit
5. Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
6. Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy
7. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
8. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
9. DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
10. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
11. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):